MedTrace Logo

Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma

NCT00365755 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-08-02

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. A bone marrow transplant, using bone marrow from the patient, may be able to replace blood-forming cells that were destroyed by chemotherapy. It is not yet know which combination chemotherapy schedule is more effective, when given before surgery and an autologous bone marrow transplant, in treating patients with disseminated neuroblastoma.

PURPOSE: This randomized phase III trial is studying two different chemotherapy schedules to compare how well they work in treating young patients who are undergoing surgery and an autologous bone marrow transplant for disseminated neuroblastoma.

Conditions

Interventions

DRUG

carboplatin

DRUG

cisplatin

DRUG

cyclophosphamide

DRUG

etoposide

DRUG

melphalan

DRUG

vincristine sulfate

PROCEDURE

autologous bone marrow transplantation

PROCEDURE

conventional surgery

Sponsors & Collaborators

  • Children's Cancer and Leukaemia Group

    lead OTHER

Principal Investigators

  • Charles Ross Pinkerton, MD · Royal Marsden NHS Foundation Trust

  • Andrew David J. Pearson, MD, FRCP, DCh · University of Newcastle Upon-Tyne

  • Ian J. Lewis, MD · Leeds Cancer Centre at St. James's University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2008-03-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00365755 on ClinicalTrials.gov